Latest Information Update: 02 Jul 2002
At a glance
- Originator Cortech
- Class Analgesics
- Mechanism of Action Bradykinin B2 receptor antagonists; Opioid mu receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 29 Feb 2000 Discontinued - Preclinical for Pain in USA (unspecified route)
- 02 Sep 1998 No-Development-Reported for Pain in USA (Unknown route)
- 17 Jul 1996 Preclinical development for Pain in USA (Unknown route)